Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Paroxysmal Nocturl Hemoglobinuria – Overview
Paroxysmal Nocturl Hemoglobinuria – Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Paroxysmal Nocturl Hemoglobinuria – Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Paroxysmal Nocturl Hemoglobinuria – Companies Involved in Therapeutics Development
Paroxysmal Nocturl Hemoglobinuria – Drug Profiles
Paroxysmal Nocturl Hemoglobinuria – Dormant Projects
Paroxysmal Nocturl Hemoglobinuria – Discontinued Products
Paroxysmal Nocturl Hemoglobinuria – Product Development Milestones
Featured News & Press Releases
Jun 12, 2022: Samsung Bioepis presents new phase 3 Study of SB12 (Eculizumab), a proposed biosimilar to Soliris, at the European Hematology Association (EHA) Congress 2022
Jun 10, 2022: CANbridge CAN106 phase 1 data presented at the European Hematology Association 2022 Congress
Jun 10, 2022: Apellis and Sobi report new data reinforcing the robust efficacy and safety profile of EMPAVELI (pegcetacoplan) for PNH at EHA 2022 Congress
May 12, 2022: Apellis announces seven abstracts in PNH to be presented at the European Hematology Association Congress
May 12, 2022: CANbridge to present CAN106 phase 1 data at the European Hematology Association 2022 Congress
Apr 08, 2022: BioCryst pauses enrollment in BCX9930 clinical trials
Mar 28, 2022: CANbridge doses first subject in Phase Ib/II PNH treatment trial in Chi
Feb 07, 2022: CANbridge reports positive top-line CAN106 Phase 1 data
Feb 04, 2022: Novartis Japan developing Iptacopan as priority product, initially targeting 3 indications
Jan 07, 2022: BioCryst begins patient enrollment in REDEEM-1 pivotal trial evaluating BCX9930 as oral monotherapy for patients with PNH
Dec 15, 2021: Apellis and Sobi announce EU approval of Aspaveli (pegcetacoplan) for treatment of PNH
Dec 13, 2021: Apellis and Sobi Report Empaveli (pegcetacoplan) demonstrated sustained normalization of clinical measures in a broad PNH patient population
Dec 11, 2021: Samsung Bioepis’ SB12 Soliris (Eculizumab) Biosimilar Demonstrates PK, PD Bioequivalence in phase 1 study
Nov 29, 2021: BioCryst begins patient enrollment in REDEEM-2 pivotal trial evaluating BCX9930 as oral monotherapy for patients with PNH
Nov 04, 2021: Apellis to present new data reinforcing EMPAVELI (pegcetacoplan) efficacy and safety in patients with PNH at the 2021 ASH Annual Meeting
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures

List of Figures
Number of Products under Development for Paroxysmal Nocturnal Hemoglobinuria, 2022
Number of Products under Development by Companies, 2022
Number of Products by Targets, 2022
Number of Products by Stage and Targets, 2022
Number of Products by Mechanism of Actions, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Top 10 Molecule Types, 2022
Number of Products by Stage and Top 10 Molecule Types, 2022

List of Tables

List of Tables
Number of Products under Development for Paroxysmal Nocturnal Hemoglobinuria, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Companies, 2022 (Contd..1)
Products under Development by Companies, 2022
Products under Development by Companies, 2022 (Contd..1)
Products under Development by Companies, 2022 (Contd..2)
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Paroxysmal Nocturnal Hemoglobinuria – Pipeline by Aevitas Therapeutics Inc, 2022
Paroxysmal Nocturnal Hemoglobinuria – Pipeline by Akari Therapeutics Plc, 2022
Paroxysmal Nocturnal Hemoglobinuria – Pipeline by Alexion Pharmaceuticals Inc, 2022
Paroxysmal Nocturnal Hemoglobinuria – Pipeline by Alnylam Pharmaceuticals Inc, 2022
Paroxysmal Nocturnal Hemoglobinuria – Pipeline by Amgen Inc, 2022
Paroxysmal Nocturnal Hemoglobinuria – Pipeline by Amyndas Pharmaceuticals LLC, 2022
Paroxysmal Nocturnal Hemoglobinuria – Pipeline by Apellis Pharmaceuticals Inc, 2022
Paroxysmal Nocturnal Hemoglobinuria – Pipeline by Arrowhead Pharmaceuticals Inc, 2022
Paroxysmal Nocturnal Hemoglobinuria – Pipeline by Attune Pharmaceuticals, 2022
Paroxysmal Nocturnal Hemoglobinuria – Pipeline by Biocad, 2022
Paroxysmal Nocturnal Hemoglobinuria – Pipeline by BioCryst Pharmaceuticals Inc, 2022
Paroxysmal Nocturnal Hemoglobinuria – Pipeline by CANbridge Life Sciences Ltd, 2022
Paroxysmal Nocturnal Hemoglobinuria – Pipeline by Chugai Pharmaceutical Co Ltd, 2022
Paroxysmal Nocturnal Hemoglobinuria – Pipeline by Homology Medicines Inc, 2022
Paroxysmal Nocturnal Hemoglobinuria – Pipeline by ImmunAbs Inc, 2022
Paroxysmal Nocturnal Hemoglobinuria – Pipeline by ISU ABXIS Co Ltd, 2022
Paroxysmal Nocturnal Hemoglobinuria – Pipeline by Kira Pharmaceuticals, 2022
Paroxysmal Nocturnal Hemoglobinuria – Pipeline by Novartis AG, 2022
Paroxysmal Nocturnal Hemoglobinuria – Pipeline by NovelMed Therapeutics Inc, 2022
Paroxysmal Nocturnal Hemoglobinuria – Pipeline by Omeros Corp, 2022
Paroxysmal Nocturnal Hemoglobinuria – Pipeline by Prestige BioPharma Ltd, 2022
Paroxysmal Nocturnal Hemoglobinuria – Pipeline by Ra Pharmaceuticals Inc, 2022
Paroxysmal Nocturnal Hemoglobinuria – Pipeline by Rallybio Corp, 2022
Paroxysmal Nocturnal Hemoglobinuria – Pipeline by Regeneron Pharmaceuticals Inc, 2022
Paroxysmal Nocturnal Hemoglobinuria – Pipeline by Samsung Bioepis Co Ltd, 2022
Paroxysmal Nocturnal Hemoglobinuria – Pipeline by Shanghai ComGen Biopharmaceutical Co Ltd, 2022
Paroxysmal Nocturnal Hemoglobinuria – Pipeline by Shanghai Meiyue Biotechnology Development Co Ltd, 2022
Paroxysmal Nocturnal Hemoglobinuria – Pipeline by Tasly Biopharmaceuticals Co Ltd, 2022
Paroxysmal Nocturnal Hemoglobinuria – Pipeline by Turgut Ilaclari AS, 2022
Paroxysmal Nocturnal Hemoglobinuria – Pipeline by Wuhan LL Science and Technology Development Co Ltd, 2022
Paroxysmal Nocturnal Hemoglobinuria – Pipeline by Zydus Lifesciences Ltd, 2022
Paroxysmal Nocturnal Hemoglobinuria – Dormant Projects, 2022
Paroxysmal Nocturnal Hemoglobinuria – Discontinued Products, 2022